Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-PSMA PET/MRI and PET/CT in Hepatocellular Carcinoma
NCT04310540Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Jun 2020
- Primary completion
- Nov 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gallium ga-68 gozetotide in hepatocellular carcinoma (HCC), sponsored by Mayo Clinic. Primary endpoints: Diagnostic performance of 68Ga-PSMA-dual contrast PET/MRI or 68Ga-PSMA PET/CT at 3 months, Treatment response after locoregional therapy in HCC at 3 months and 1 more. Started Jun 2020; status: completed.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04310540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04310540.